Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAP1A Variant rs7525578 Modifies Glycemic Response to Metformin But Not to Pioglitazone or Gliclazide in the UK Biobank.

Clinical neuropharmacology - 1 Jan 2026

Lehrer Steven, Rheinstein Peter

Abstract excerpt

OBJECTIVES: Metformin is the first-line treatment for type 2 diabetes (T2D), yet interindividual variability in glycemic response remains poorly understood. Preclinical studies demonstrate that low-dose metformin lowers glucose via Rap1 signaling in ventromedial hypothalamic neurons, a pathway not required for sulfonylurea or thiazolidinedione efficacy. We investigated whether a common intronic RAP1A variant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycated Hemoglobin
Share to Hypoglycemic Agents
Share to Metformin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pioglitazone

Share to rap1 GTP-Binding Proteins

Share to Shelterin Complex

Share to Telomere-Binding Proteins

Share to UK Biobank

Source

Identifiers

PMID: 41529235
DOI: 10.1097/WNF.0000000000000659

Genes

RAP1A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAP1A Variant rs7525578 Modifies Glycemic Response to Metformin But Not to Pioglitazone or Gliclazide in the UK Biobank.PMID 41529235Read ↗

Genome-wide association analysis identifies ancestry-specific genetic variation associated with medication response in the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH)Semantic proximity Read ↗

Personalized medicine in diabetes: the role of ‘omics’ and biomarkersSemantic proximity Read ↗

Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH.Semantic proximity Read ↗

Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program.Semantic proximity Read ↗

The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes.Semantic proximity Read ↗

Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study.Semantic proximity Read ↗

Diabetes: Genetic variation underpins metformin response.Semantic proximity Read ↗

Impact of PRKAA2 and LKB1 genetic variants on metabolic alterations in response to metformin-sulfonylurea therapy.Semantic proximity Read ↗

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicineSemantic proximity Read ↗

An Update on the Pharmacogenomics of Metformin: Progress, Problems and PotentialSemantic proximity Read ↗

The pharmacogenetics of metformin.Semantic proximity Read ↗

Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.